MedPanel, a leader in online
medical market intelligence, announces the launch of Profiles in Non-Small
Cell Lung Cancer -- United States & Europe, the final release in its
2005-2006 Profiles in Oncology series. Profiles is a subscription service
delivering four highly detailed, cancer-specific studies on a quarterly
basis. Profiles studies evaluate clinical and commercial market
opportunities for both current and emerging oncology products. Profiles is
designed to provide in-depth analysis for organizations and companies
considering the development, acquisition or launch of a novel therapeutic
agent. The studies explore best practices, key outcomes measures, unmet
medical needs, and future direction of treatment for a given indication
while quantifying the trade-offs associated with varying levels of clinical
performance on an agent-specific basis. The latest study offers analysis of
treatment of the advanced and metastatic patient population.
According to the World Health Organization (WHO), more than 1.2 million
cases of lung cancer are diagnosed worldwide each year, and approximately
1.1 million deaths are attributed to lung cancer annually. Approximately
80% of lung cancer cases are characterized as non-small cell lung cancer
(NSCLC).
According to the American Cancer Society, lung cancer accounts for 28%
of cancer deaths, making it the single largest cause of cancer deaths in
the United States. It is estimated that more than 172,000 new cases of lung
cancer will be diagnosed in the United States in 2006 and more than 163,000
people will die of the disease this year. This translates into
approximately 137,600 new cases and 130,400 deaths associated with the
non-small cell form of the disease in 2006. For Stage IV patients, one-year
survival is estimated at roughly 20% with five-year survival at 1%. In
Europe, the WHO estimates more than 375,000 new cases of lung cancer are
diagnosed each year and more than 347,000 deaths are recorded. In terms of
NSCLC, the figures approximate 300,000 new cases and 277,600 deaths
annually.
"Profiles in Non-Small Cell Lung Cancer is an indispensable tool for
drug developers in their efforts to fulfill the unmet need in this tumor
type," said Priya Bhargava, Vice President of Content Development at
MedPanel. "The combination of current market assessment with future
landscape analysis provides the foundation necessary for successful product
development. Clinical profile evaluation and competitive intelligence on
investigational agents are just some of the insights Profiles provides."
Dr. Nina Karlin, of UCLA, said, "MedPanel offers the ideal platform for
discussion of novel approaches to treating non-small cell lung cancer. Such
an approach stimulates fruitful interaction among community and academic
oncologists and is critical for the dissemination of recent advances and
burgeoning research."
About MedPanel
MedPanel is a medical market intelligence company providing custom and
syndicated medical market research exclusively online. MedPanel's powerful
proprietary methodology and platform enable pharmaceutical, biotechnology,
medical device, diagnostics companies, as well as others with an interest
in life sciences, to have greater strategic control over the development
and commercialization of products, and lower costs overall. Through
unparalleled access to clinicians, medical thought leaders and healthcare
professionals, and through its interactive, asynchronous approach to
medical panels and surveys, MedPanel is able to deliver fast, unbiased,
cost-effective and actionable data. MedPanel is a global organization based
in Cambridge, Massachusetts.
MedPanel
medpanel